Sunday 21 January 2018

Trinity Biotech profits up 12pc

John Mulligan

John Mulligan

Operating profits at Bray-based medical test manufacturer Trinity Biotech increased by over 12pc last year to just over $15.8m (€12m).

Unveiling full-year results yesterday, the company reported lower revenues, which fell 13pc to $78m. But the group's cost of sales also declined, falling 17pc to $37.8m, helping to boost the bottom line.

Trinity Biotech, which is listed on the Nasdaq in New York, sells kits used to detect a range of infectious diseases including mumps, measles and syphilis.

Its sales fell year-on-year in 2011 after it sold its coagulation business in the second quarter of 2010 for $90m.

The bulk of that money was received immediately by Trinity Biotech, which used the proceeds to eliminate its debt and leave it with a strong cash balance.

The sale also saw 320 Trinity Biotech employees move to the French buyer, Stago.

Chief executive Ronan O Caoimh said he was "very pleased" with the performance in 2011. He said it showed "significant improvement" in all indicators, with over $12m of free cash flow having been generated.

Shares in Trinity Biotech were down slightly in early morning trading in New York.

Irish Independent

Promoted Links

Business Newsletter

Read the leading stories from the world of Business.

Promoted Links

Also in Business